Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Camrelizumab |
Indication/Tumor Type | esophagus squamous cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | esophagus squamous cell carcinoma | predicted - sensitive | Camrelizumab | Phase I | Actionable | In a Phase I trial, Camrelizumab (SHR-1210) treatment resulted improved objective response rate (46.7%, 7/15 vs 11.1%, 1/9, p>0.05) and disease control rate (66.7%, 10/15 vs 33.3%, 3/9) in patients with CD274 (PD-L1)-positive advanced esophageal squamous cell carcinoma compared to patients with CD274 (PD-L1)-negative tumors (PMID: 29358502; NCT02742935). | 29358502 |
PubMed Id | Reference Title | Details |
---|---|---|
(29358502) | Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. | Full reference... |